Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities-Reference-Cited by-同舟云学术

Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities

Published:2000-11 Issue:9 Volume:26 Page:985-991
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Furlong T,Storb R,Anasetti C,Appelbaum FR,Deeg HJ,Doney K,Martin P,Sullivan K,Witherspoon R,Nash RA

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1702639.pdf

Reference52 articles.

1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia New Engl J Med 1986 314: 729–735

2. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease Blood 1986 68: 119–125

3. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies Transplantation 1991 51: 443–447

4. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program New Engl J Med 1993 328: 593–602

5. Anasetti C, Beatty PG, Storb R et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma Hum Immunol 1990 29: 79–91

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency;Transplantation and Cellular Therapy;2021-12

2. Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation;Clinical Transplantation;2021-05-03

3. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease;Blood;2020-01-02

4. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy;Journal of Oncology Pharmacy Practice;2018-08-19

5. Tacrolimus: An updated review on delivering strategies for multifarious diseases;European Journal of Pharmaceutical Sciences;2018-03